Nasdaq · Healthcare
Embecta Corp. (EMBC)
As-reported financials and recent SEC filings for Embecta Corp., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.08B
Net income
$95.4M
Net margin
8.8%
Diluted EPS
$1.62
ROE
-14.7%
P/E (TTM)
1.8×
Market cap
$207.1M
Debt / equity
-2.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $1.08B | $1.12B | $1.12B | $1.13B | $1.17B |
| Gross profit | $676.8M | $735.2M | $749.9M | $774.9M | $800.4M |
| Operating income | $242.1M | $166.8M | $221.5M | $309.6M | $492.0M |
| Net income | $95.4M | $78.3M | $70.4M | $223.6M | $414.8M |
| Diluted EPS | $1.62 | $1.34 | $1.22 | $3.89 | $7.28 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-02
View on EDGAR →SCHEDULE 13G/A2026-05-27
View on EDGAR →SD2026-05-22
View on EDGAR →8-K2026-05-15
View on EDGAR →10-Q2026-05-05
View on EDGAR →8-K2026-05-05
View on EDGAR →SCHEDULE 13G2026-05-05
View on EDGAR →SCHEDULE 13G/A2026-05-01
View on EDGAR →Go deeper on EMBC
Search Embecta Corp.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.